XMT-1536 Interim Expansion Data from Phase 1 Study May 27, 2020 Legal Disclaimer This presentation contains "forward-looking" statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Company's business strategy and the design, progression and timing of its clinical tri ...

XMT-1536 临床试验结果 - XMT-1536 是一种新型的 NaPi2b 靶向抗体药物偶联物 (ADC)，用于治疗既往接受过治疗的转移性卵巢癌 (OC) 或非小细胞肺癌 (NSCLC) 患者[1] - 在铂耐药性卵巢癌 (OC) 患者中，标准治疗（如单药聚乙二醇脂质体阿霉素和拓扑替康）的疗效有限，缓解率为 4% 至 12%，中位无进展生存期为 3 至 4 个月[1] - 在 NSCLC 腺癌患者中，尽管治疗选择有所进展，但临床结果仍然较差，二线和后续化疗的缓解率为 12% 至 20%[1] - 最大耐受剂量 (MTD) 确定为 43 mg/m2，这是目前正在扩展中评估的剂量[1] 安全性与耐受性 - 大多数治疗相关不良事件 (TRAE) 为 1 级或 2 级[1] - 28 名患者 (82%) 报告了至少 1 起治疗相关不良事件 (TRAE)[1] - 常见的 TRAE（≥20%）包括疲劳、恶心、呕吐、发热、食欲下降、腹泻、AST 升高（短暂性）[1] - 没有报告 4 级或 5 级 TRAE[1] - 没有报告 ≥3 级（严重）的中性粒细胞减少症、周围神经病变或眼部毒性[1] - 18 起严重不良事件 (SAE) 在 10 名患者 (29%) 中报告[1] 疗效 - 在铂耐药性 OC 患者中观察到抗肿瘤活性[1] - 在 20 名可评估的卵巢癌患者中，完全缓解 (CR) 为 2 例 (10%)[1] - 在铂耐药性 OC 患者中，客观缓解率 (ORR) 为 35%（不包括 1 名未确认 PR 的患者）[1] - 疾病控制率 (DCR) 为 80%[1]

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2020 Earnings Conference Call May 8, 2020 8:00 AM ET Company Participants Sarah Carmody ??? Executive Director-Investor Relations and Corporate Communications Anna Protopapas ??? President and Chief Executive Officer Dirk Huebner ??? Chief Medical Officer Tim Lowinger ??? Chief Science and Technology Officer Brian DeSchuytner ??? Senior Vice President-Finance and Product Strategy Eva Jack ??? Chief Business Officer Conference Call Participants Jonathan Chang ??? S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38129 Mersana Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or o ...

T H E R A P E U T I C S Accelerating ADC Innovation …because patients are waiting March 2020 Legal Disclaimer This presentation contains "forward-looking" statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Company's business strategy and the design, progression a ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2019 Results Conference Call February 28, 2020 8:00 AM ET Company Participants Sarah Carmody - Executive Director, IR and Corporate Communications Anna Protopapas - CEO Brian DeSchuytner - SVP, Finance and Product Strategy Conference Call Participants Jonathan Chang - SVB Leerink Boris Peaker - Cowen Debjit Chattopadhyay - H.C. Wainwright Jessica Fye - JP Morgan Mike Ulz - Baird David Nierengarten - Wedbush Securities Operator Good morning, and welcome to Mersana ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38129 Mersana Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdicti ...

THERAPEUTICS Accelerating ADC Innovation …because patients are waiting 38th Annual JP Morgan Healthcare Conference January 16, 2020 Legal Disclaimer This presentation contains "forward-looking" statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Company's business ...

Financial Data and Key Metrics Changes - The company ended Q3 2019 with $112 million in cash, cash equivalents, and marketable securities, having used net cash of $16.3 million in operations during the quarter [29] - Net loss for Q3 2019 was $16.8 million or $0.35 per share, compared to a net loss of $17.1 million or $0.74 per share for the same period in 2018 [31] - Collaboration revenue for Q3 2019 was approximately $0.8 million, down from $2.2 million in Q3 2018, primarily due to a decrease in services performed in support of partners' programs [30] Business Line Data and Key Metrics Changes - Research and development expenses for Q3 2019 were approximately $13.7 million, down from $15.2 million in Q3 2018, driven by a decrease in manufacturing costs for XMT-1536 and XMT-1522 [30] - General and administrative expenses remained flat at $4.4 million compared to the same period in 2018 [31] Market Data and Key Metrics Changes - The company noted substantial interest in pursuing accelerated registration strategies for XMT-1536 based on discussions with investigators and emerging profiles [28] - Data presented at ESMO indicated a potential paradigm shift in the standard of care for first-line ovarian cancer, increasing the need for new mechanisms of action in later lines and platinum-resistant patients [26] Company Strategy and Development Direction - Mersana is focused on achieving proof-of-concept in multiple data readouts in 2020, with plans to report data from the full dose escalation portion of the XMT-1536 study and early data from ovarian and lung cohorts [33] - The company aims to file an IND and enter the clinic with its next ADC candidate in the first half of 2020, while also strengthening its discovery pipeline [34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the continued safety and efficacy profile of XMT-1536, indicating that 2020 will be a data-rich year with multiple potential inflection points [10][33] - The company is well-capitalized to execute its plans through mid-2021, with a cash balance of $112 million [35] Other Important Information - The company is leveraging its Dolaflexin, Dolasynthen, and Immunosynthen platforms to build a robust discovery pipeline for mid- to long-term growth [12] - The ongoing expansion study for XMT-1536 is evaluating patients with platinum-resistant ovarian cancer and NSCLC adenocarcinoma, with strong investigator interest and rapid site initiation [16] Q&A Session Summary Question: What is the experience at the 30 and 36 mg/m² cohorts? - The experience has been positive, with patients staying on study for extended periods and efficacy observed in doses between 20 and up [43] Question: Are there any durable responses beyond 4 months? - Management pointed to the ASCO poster as the last data disclosure, with plans to disclose full dose escalation and expansion datasets in 2020 [45] Question: What are the thoughts on the diagnostic and utilization in the ongoing expansion cohort? - A robust diagnostic has been developed and validated, being used in expansion cohorts to collect data on tissue expression levels [46] Question: Is the pharmacokinetic profile dose proportional? - Yes, the pharmacokinetic profile is dose proportional, with no accumulation observed over the current dosing schedule [48] Question: What is the pace of enrollment in the expansion study? - Enrollment is going very well, with the number of sites initiated ahead of schedule due to investigator enthusiasm [57]

FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38129 Mersana Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation ...